Stay updated on Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial

Sign up to get notified when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase III clinical trial evaluating the efficacy and safety of single agent Belantamab Mafodotin compared to Pomalidomide plus low-dose Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:12.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments. Additionally, specific criteria for participants in the Republic of Korea and other detailed inclusion and exclusion criteria have been added.
    Difference
    42%
    Check dated 2024-05-22T21:24:40.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:33:35.000Z thumbnail image

Stay in the know with updates to Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.